This bispecific antibody targets B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T cells, providing a promising treatment option for relapsed or refractory multiple myeloma. This evidence concerns the gene TNFRSF17 and AL amyloidosis.